CTRI/2018/04/013525已完成不适用
A COMPARATIVE CLINICAL STUDY OF VAMANA KARMA AND CHITRAKADIKWATH IN THE MANAGEMENT OF STHOOL PRAMEHI W.S.R. TO TYPE 2 DIABETES MELLITUS
GOVERMENT AKANDANAND AYURVED COLLEGE AHMEDABAD1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2017年5月31日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- All the signs and symptoms of Pramehi will be assigned score depending upone their severity to assess the effect of the drugsat the time of before treatment and after treatment.
研究概览
简要总结
This study is rendomised, participiant,blinded,parellel group,active controlled trial to compare the efficasy of chitarakadikwath 40 ml bd with or without vaman karma with the dutation of 6weeks after vaman karma in 30 patienis of sthool prameha.Which will be conducted in india.
研究设计
- 研究类型
- Interventional
- 分配方式
- Coin toss, Lottery, toss of dice, shuffling cards etc
- 盲法
- Participant Blinded
入排标准
- 年龄范围
- 16.00 Year(s) 至 60.00 Year(s)（—）
- 性别
- All
入选标准
- •Patient having classical signs and symptoms of the disease according to Ayurveda well as Modern science. 1 Patients of Prameha having BMI 25 to 35 2 Patient of NIDDM with blood sugar level more then.
- •F.B.S.- 126 mg/dl or P.P.B.S.-180 mg/dl. 3 Age group of 16-60 years. 4 Disease chronicity 10 year. 5 Patient otherwise healthy and fit for Shodhana(Vamana) and Chirakadikwath as per the Ayurvedic text.
排除标准
- •Patients of Prameha having BMI < 25 &>35 1 Patients of Type-1 Diabetes or the patients of Type-2 Diabetes taking Insulin.
- •2 Patients having complications of Diabetes like Nephropathy, Retinopathy, Diabetic Foot,Carbuncles etc.
- •3 Age <16 to > 60 years.
- •4 Patients having Diabetes in association with other endocrinopathies like Pheochromocytoma, Acromegaly, Cushing’s syndrome, Hyperthyroidism etc.
- •5 Patients having drug or chemical induced Type-II Diabetes, like glucocorticoids induced or thyroid hormone induced etc.
- •6 Patients with genetic syndromes associated with Type-II Diabetes like Down’s syndrome, Klinefelter’s Syndrome, and Turner’s syndrome etc.
- •7 Patients complicated with any cardiovascular diseases, renal diseases, Carcinoma or any other disease effecting multiple body systems and pregnant women etc.
结局指标
主要结局
All the signs and symptoms of Pramehi will be assigned score depending upone their severity to assess the effect of the drugsat the time of before treatment and after treatment.
时间窗: After 3 months
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
2 期
A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLDPolycystic Liver DiseaseNCT05281328Camurus AB71
已完成
4 期
A Comparative Efficacy and Safety Study of Compound Carraghenates Cream With Mayinglong Musk Hemorrhoid Ointment in the Treatment of HemorrhoidsHemorrhoidsNCT01881282Xian-Janssen Pharmaceutical Ltd.123
已完成
1 期
Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris®Healthy SubjectsNCT04027803Biocad78
已完成
不适用
Comparison of Therapy in Treatment of Patients With Helicobacter Pylori Infection: Concomitant Versus Hybrid Therapy.Helicobacter Pylori InfectionNCT03572777Antonio Mestrovic159
已完成
1 期
A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III MelanomaMelanomaNCT06153238Sandoz322